Sacubitril/Valsartan, Angiotensin-Converting Enzyme (ACE) Inhibitors, and Other Angiotensin II Receptor Blockers (ARBs) Use in Patients with Heart Failure

    Basic Details
    Date Posted
    Tuesday, August 25, 2020
    Status
    Complete
    Medical Product
    angiotensin II receptor blocker (ARB)
    angiotensin-converting enzyme (ACE) inhibitor
    sacubitril/valsartan
    Description

    In this analysis we examined counts of new users of sacubitril/valsartan, angiotensin-converting enzyme (ACE) inhibitors, and other angiotensin II receptor blockers (ARBs) with heart failure in the Sentinel Distributed Database (SDD). We also captured switching between products.

    This analysis include two reports containing data from 16 Data Partners contributing to the SDD. Data from January 1, 2015 to July 31, 2019 were included in Report 1, which was distributed on December 6, 2019. Data from January 1, 2015 to July 31, 2019 were included in Report 2, which was distributed on February 27, 2020.

    Additional Details
    FDA Center
    CDER
    Time Period
    January 1, 2015 - July 31, 2019
    Study Type
    Modular Program
    Assessment Type
    Exploratory Analyses
    Population / Cohort
    Individuals 18 years of age and older
    Data Sources
    Sentinel Distributed Database (SDD)